Tasigna mechanism of action
Tasigna mechanism of action
Nilotinib (AMN107), selective Abl inhibitor, is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib while being significantly more potent compared with imatinib (IC 50. [12] It is a substrate for CYP3A4 and hence grapefruit juice and other CYP3A4 inhibitors [13] will increase its action and inducers like St. Active against 32 out of the 33 Bcr-Abl mutations* resistant to Glivec®2. Druker tasigna mechanism of action BJ, Guilhot F, O'Brien SG, et al. John's wort [14] will decrease it. 2 DOSAGE AND ADMINISTRATION Recommended Dosage. Pharmacology Mechanism of Action. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML). Tasigna is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy. Mechanism of action Chronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Patients report that pomegranates and starfruit may also interfere Tasigna: 50 mg, 150 mg, 200 mg. Nilotinib inhibits the tyrosine kinase activity of the tasigna mechanism of action BCR-ABL protein Nilotinib is an inhibitor of OATP-1B1 transporter but not for OATP-1B3. The mild side effects of Tasigna that are less common** can include: hair loss dry skin belly pain, indigestion, or gastroenteritis (an infection in your digestive tract) weakness muscle pain or.